Insider · CIK 0001016835
Rory B Riggs
directorceoofficerowner
Files at ITCI (Intra-Cellular Therapies, Inc.), CBUS (Cibus, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 9, 2025 | CBUS Cibus, Inc. | XIn-the-money exercise Class A Common Stock | +4,000,000 | $0.00 | $400 | 14,533,307 | Jun 11, 2025 |
| Jun 9, 2025 | CBUS Cibus, Inc. | XIn-the-money exercise Class A Common Stock | +50,000 | $0.01 | $500 | 14,583,307 | Jun 11, 2025 |
| Jun 9, 2025 | CBUS Cibus, Inc. | XIn-the-money exercise Pre-Funded Warrant (right to buy)derivative | -4,000,000 | $0.00 | $0 | 0 | Jun 11, 2025 |
| Jun 9, 2025 | CBUS Cibus, Inc. | XIn-the-money exercise Pre-Funded Warrant (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Jun 11, 2025 |
| Jun 5, 2025 | CBUS Cibus, Inc. | AGrant or award Class A Common Stock | +5,714,286 | $1.75 | $10M | 10,533,307 | Jun 10, 2025 |
| May 22, 2025 | CBUS Cibus, Inc. | AGrant or award Stock Option (Right-to-Buy)derivative | +39,301 | $0.00 | $0 | 39,301 | May 27, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Common Stock | -131,512 | $132.00 | $17M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -16,757 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -7,009 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -4,322 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -2,951 | - | - | 0 | Apr 2, 2025 |
| Jan 21, 2025 | CBUS Cibus, Inc. | AGrant or award Common Warrantderivative | +4,000,000 | - | - | 4,000,000 | Jan 23, 2025 |
| Jan 21, 2025 | CBUS Cibus, Inc. | AGrant or award Pre-Funded Warrantderivative | +4,000,000 | $2.50 | $10.0M | 4,000,000 | Jan 23, 2025 |
| Dec 31, 2024 | CBUS Cibus, Inc. | CConversion Class B Common Stock | -1,388,084 | - | - | 0 | Jan 10, 2025 |
| Dec 31, 2024 | CBUS Cibus, Inc. | CConversion Class A Common Stock | +1,388,084 | - | - | 4,839,912 | Jan 10, 2025 |
| Dec 31, 2024 | CBUS Cibus, Inc. | CConversion Cibus Common Unitderivative | -1,388,084 | - | - | 0 | Jan 10, 2025 |
| Dec 31, 2024 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Common Stock | +215 | $83.52 | $18k | 131,512 | Jan 3, 2025 |
| Jun 18, 2019 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock | +14,189 | - | - | 131,297 | Oct 15, 2024 |
| Jun 18, 2019 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Restricted Stock Unitsderivative | -14,189 | $0.00 | $0 | 0 | Oct 15, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.